Ethics, Equity, Training and the Future of Psychedelic Practice
Psychedelic-Assisted Medicine: Science and Practice
Learning objectives for this lesson:
- Explain how the altered state produced by a psychedelic changes decision-making, suggestibility and vulnerability, and why consent is obtained while the person is sober.
- Compare the rules on touch, relationships and supervision in Health Canada's trial expectations, Oregon's rules and Canadian professional guidance, with their dates.
- Analyze the 2019 disclosure from a Canadian MDMA trial site to show what supervision, recording, co-therapy and regulation can and cannot prevent.
- Describe who may prescribe and deliver psychedelic-assisted therapy in British Columbia and compare Canadian and international training programs and competency frameworks as of October 2026.
- Weigh the arguments for and against experiential training and explain the Canadian legal position on it.
- Apply the ethical principles of traditional Indigenous medicine, Two-Eyed Seeing, Canadian and British Columbia commitments to Indigenous peoples and the Nagoya Protocol to questions of reciprocity and benefit sharing.
- Evaluate the diversity of trial samples and estimate the clinician time and cost of a course of therapy, relating both to equity of access.
- Evaluate patents, investor financing, clinic chains and marketing claims using dated Canadian and international cases and rules, and explain where new compounds and a research agenda fit in the field's future.
- Design a responsible psychedelic service in British Columbia that integrates the trial evidence, the lawful access routes, and the ethics and equity principles of the course.
This course was developed by Dr. Kiffer G. Card.
Ethics in Altered States: Consent, Touch, Boundaries, Power and Supervision
Content note. This section discusses boundary violations and sexual misconduct by therapists, including a case from a clinical trial site in British Columbia. If you would like support, VictimLinkBC offers confidential support to people affected by sexual violence in British Columbia by call or text at 1-800-563-0808, the 9-8-8 Suicide Crisis Helpline is available by call or text at 9-8-8, and the Hope for Wellness Help Line for Indigenous people can be reached at 1-855-242-3310.
Introduction
Lesson 7 described psychedelic-assisted therapy as a process of screening, preparation, one or a few supervised dosing sessions, and integration. Its ethics rest on principles that all health professions share (respect for a person's choices, acting for the person's benefit, avoiding harm, and fairness), applied to an unusual situation: for several hours the person is in an altered state that the treatment produces, with practitioners who hold almost all of the practical power.
The parts below cover the altered state, informed consent, the rules on touch and sexual misconduct, the 2019 disclosure from a Canadian MDMA trial site, and the safeguards around the practitioner. Lesson 9 treated the misconduct disclosed at a Canadian MDMA trial site in 2019 as a question of research integrity; here the same case shows what each safeguard can and cannot do.
Learning Objectives
- 1.1 Explain how the altered state produced by a psychedelic changes decision-making, suggestibility and vulnerability, define transference, countertransference and boundary drift, and explain why these changes raise the ethical stakes of psychedelic-assisted therapy.
- 1.2 Describe the seven components of informed consent proposed for psychedelic medicine and explain why consent is obtained while the person is sober and renewed over time.
- 2.1 Compare how Health Canada's trial expectations, Oregon's rules and Canadian professional guidance govern touch, relationships and supervision, with dates.
- 3.1 Describe the 2019 disclosure from a Canadian MDMA trial site and explain why each safeguard in place failed to prevent the misconduct.
- 3.2 Explain how power operates in a dosing session, and describe the roles and limits of supervision, documentation and the practitioner's own inner work as safeguards.
1.1 Why the Altered State Raises the Ethical Stakes
A dosing session differs from an ordinary therapy appointment in its length, its intensity and the person's limited capacity to change course once the drug has been taken. Four features of the altered state each weaken a protection that ordinary consent takes for granted.
1.1.1 Decision-Making That Cannot Easily Be Revisited
Decision-making capacity is the ability to understand information, weigh it and communicate a choice. In a dosing session the effects of the drug continue for hours whatever the person decides; experimental sessions in the phase 3 trials of MDMA-assisted therapy lasted about eight hours (Mitchell et al., 2021, 2023). A person can still refuse an action during a session, and practitioners must respect that refusal, but a new request made at the peak of a session may reflect the drug's effects as much as the person's settled wishes.
1.1.2 Suggestibility
Suggestibility is the tendency to accept and act on suggestions from another person. In a placebo-controlled study of ten healthy volunteers, intravenous LSD (40 to 80 micrograms) increased ratings on a standard suggestibility scale (Carhart-Harris et al., 2015). The study was very small and used a laboratory measure, so its finding is an early one and research on the question is evolving. It suggests that a practitioner's words and expectations may carry more weight than usual, one reason trial models describe a non-directive stance (Lesson 7).
1.1.3 Vulnerability, Regression and Transference
People in a dosing session often revisit painful memories, feel intense love, fear or grief, and rely on the practitioners for safety. These conditions intensify transference and countertransference, defined in the cards below. The code of ethics of a Canadian graduate training program names transference, countertransference and authority dynamics as reasons to keep clear boundaries, manage power carefully and avoid dual relationships (Dames et al., 2026).
1.1.4 Experiences That Are Hard to Describe in Advance
Written consent assumes that a person can understand in advance what they are agreeing to. Marks et al. (2024) argue that consent to psychedelic treatment is complicated by features of the drugs and of how they are given, including possible lasting changes in beliefs and the difficulty of conveying what a session will feel like.
Click each card below for a definition and an example of six terms used in this section.
Taken together, these features explain why safeguards concentrate on what is agreed before the drug is taken and on who is watching while it acts, beginning with informed consent.
1.2 Informed Consent for an Experience That Is Hard to Describe
Informed consent is a process in which a person with capacity receives the information they need, understands it, and agrees voluntarily. In psychedelic-assisted therapy that process covers the drug, the therapy, the legal route through which the drug is given, and the unusual risks of the altered state.
1.2.1 Seven Components of Consent
Marks et al. (2024) proposed seven essential components of consent to psychedelic medicine outside research and noted that public consent documents for psychedelic trials often overlooked or underemphasized them. Table 12.1 lists the components and explains, in this lesson's words, why each matters in an altered state.
Table 12.1. Seven components of informed consent to psychedelic medicine identified by Marks et al. (2024), with the reason each matters in an altered state.
| Component (Marks et al., 2024) | Why it matters when consciousness is altered | Where the course develops it |
|---|---|---|
| Short-term and long-term perceptual disturbances | A person cannot judge in advance how intense perceptual changes will be, and a small number of people report changes that persist after use. | Lesson 6 |
| Possible personality changes and altered metaphysical beliefs | Some people report lasting changes in their beliefs about the self, meaning or the nature of reality, which they may welcome or regret. | Lesson 5 |
| The limited role of reassuring physical touch | Touch can calm distress, and it can also be misread or misused when judgement and boundaries are altered. | 2.1 Touch, Boundaries and Sexual Misconduct |
| The potential for patient abuse or coercion | Suggestibility, dependence on the team and the inability to leave make exploitation possible, so consent documents can name the risk and the route for reporting it. | Case 12.1; Lesson 9 |
| The role and risks of data collection | Video, physiological readings and questionnaires may be stored and shared, and recordings protect participants only when someone reviews them and access is controlled. | 3.2 Power, Supervision, Documentation and the Practitioner's Inner Work |
| Relevant practitioner disclosures | Financial interests, training and personal views about psychedelics can shape advice, and disclosure lets the person weigh them. | Sections 2 and 4 |
| Interactive education and assessment of comprehension | A form cannot convey the experience well, so understanding is checked through conversation and questions over several meetings. | Lesson 7 |
1.2.2 Consent Obtained While Sober, and Renewed over Time
The practical answer to altered decision-making is timing. Health Canada's expectations for clinical trials of psychedelic-assisted psychotherapy, published on 5 December 2022, state that consent for touch should be obtained before the investigational product is given and that consent should be obtained first if sessions are video-recorded (Health Canada, 2022). As of October 2026, Oregon's rules require a preparation session at least 24 hours and no more than 90 days before the first administration session, prior written consent to any supportive touch, and a signed consent form stating that psilocybin services are not a medical or clinical treatment (OAR 333-333-5000 and 333-333-5040). The course shares the practitioners' standard that consent is obtained while the person is sober, that the person may withdraw at any time before the drug is given, and that consent is revisited in integration before any further session.
Figure 12.1 shows where each kind of agreement belongs in the four phases. During the dosing session the team honours agreements already made, responding to any new request within them and recording it for discussion once the person is sober.
1.2.3 Consent to the Legal Route
In Canada, practitioners can lawfully give or support the use of a controlled psychedelic only through a clinical trial, the Special Access Program (SAP), or an exemption under section 56 of the Controlled Drugs and Substances Act (Lesson 11), so consent includes an honest account of the route. Health Canada's notice of 27 February 2023 on SAP requests states that an authorization "is not a broad statement or opinion that the drug is safe, efficacious or of high quality" (Health Canada, 2023). Lesson 7 explained the legal risk to a regulated professional who supports unauthorized use.
Consent sets the terms of the relationship. The next part turns to the boundary around touch and sexual contact.
2.1 Touch, Boundaries and Sexual Misconduct
A hand held during a frightening passage can help a person feel safe. The same contact can be experienced as intrusive or misread by a person whose perceptions are altered, and it can become a step toward exploitation, which is why Marks et al. (2024) include the limited role of reassuring touch in consent.
2.1.1 How Current Rules Define Acceptable Touch
Rules on touch differ by setting and are recent. Table 12.2 compares Health Canada's trial expectations, Oregon's rules for licensed psilocybin services, guidance for registered clinical counsellors in British Columbia, and the code of ethics of a Canadian graduate training program. Oregon's rule is the most specific, permitting supportive touch only on the client's request with prior written consent, and only as hugs or hands on the client's hands, feet or shoulders (OAR 333-333-5120).
Table 12.2. Rules on touch, relationships and supervision in four sources, as published or in force in October 2026.
| Source and date | Applies to | Touch | Relationships and boundaries | Team and supervision |
|---|---|---|---|---|
| Health Canada, expectations for trials of psychedelic-assisted psychotherapy (5 December 2022) | Clinical trials in Canada | Any contact must be non-intimate and non-sexual; consent for touch obtained before the drug is given and again in the moment | Consent obtained before any video recording | At least two therapists present; a physician readily available on site; unlicensed team members directly supervised by a licensed therapist; check-in visits in the following days and weeks |
| Oregon Administrative Rules, chapter 333, division 333 (current October 2026) | Licensed psilocybin facilitators and service centres | Supportive touch only on request with prior written consent; limited to hugs or hands on the client's hands, feet or shoulders | No romantic relationship or sexual contact during services, or with the client, the client's partner or immediate family for one year after the last service | Facilitator present for preparation, administration and integration; licensees told clients they have a duty to report misconduct |
| BC Association of Clinical Counsellors (BCACC), guidance on psychedelics (October 2024) | Registered clinical counsellors who are association members | Measured against standards on client-centred consent | Standards on relationships, boundaries and conflict of interest, and on sexual misconduct | Training, supervision and work within a multidisciplinary team; services offered only to sanctioned trials or programs |
| Dames et al. (2026), code of ethics of a Canadian graduate program | Learners and faculty | Explicit advance consent and a defined purpose | Sexual boundaries described as unequivocal | Active supervision of sexual countertransference |
Sources: Health Canada (2022); OAR 333-333-5000, 333-333-5040 and 333-333-5120; BCACC (2024); Dames et al. (2026).
2.1.2 Zero Tolerance for Sexual or Romantic Contact
Every source in Table 12.2 prohibits sexual contact with a client, and the course adopts the practitioners' standard of zero tolerance for the reasons given in 1.1 Why the Altered State Raises the Ethical Stakes. Oregon extends the prohibition to the year after the last service and to the client's partner and family (OAR 333-333-5120), recognizing that the power difference created during treatment persists, as Case 12.1 illustrates.
3.1 The 2019 Disclosure: What the Case Shows about Safeguards
Case 12.1 describes a disclosure from a Canadian trial site at which the safeguards described so far were in place, and it shows what each of them can and cannot prevent.
On 24 May 2019 the Multidisciplinary Association for Psychedelic Studies (MAPS) disclosed ethical violations by two co-therapists who were sub-investigators at a MAPS-sponsored phase 2 trial of MDMA-assisted therapy in British Columbia (ClinicalTrials.gov NCT01958593). According to the statement, the participant completed active treatment on 7 October 2015 but remained enrolled until a long-term follow-up visit in June 2016, the therapists continued to provide her with therapy, and at the end of 2015 or early 2016 her relationship with one of the therapists became sexual; the other therapist reportedly tried to stop it and did not report it. In October 2018 the participant forwarded to MAPS the complaints she had filed with two British Columbia regulatory colleges in January 2018, and MAPS then reported the matter to the United States Food and Drug Administration, Health Canada and the ethics committee, barred both therapists, and paid the participant 15,000 Canadian dollars toward therapy (MAPS, 2019/2022).
The statement listed the protections in place, namely two providers at every visit, video recording, monitoring and clinical supervision, and concluded, "In this case, none of these measures were sufficient." A March 2022 update, issued after a reporter had viewed session videos, stated that a reopened review was ongoing and that MAPS had "provisionally determined" that the therapists "substantially deviated from the MDMA-assisted Therapy Treatment Manual on several occasions during the treatment period" (MAPS, 2019/2022). The Canadian Broadcasting Corporation reported that the therapist was not a licensed psychologist in British Columbia, so no official body could investigate him, that Crown prosecutors declined to approve charges recommended by police, and that a civil lawsuit, in which the participant alleged sexual assault and which the therapist contested, was settled out of court (CBC News, 2022). The participant has since spoken publicly about the case (CBC News, 2022).
Each safeguard in Case 12.1 was present and failed for an identifiable reason. One co-therapist did not report the other. The video became a check only when people outside the team viewed it, years later, and supervision depended on what supervisors were told or shown. The sexual relationship began after the active treatment sessions, outside the recorded therapy visits, and the therapist involved was outside any British Columbia regulator's jurisdiction. The case points toward independence within teams, routine review of recordings, reporting duties for every team member, rules for the period after treatment, and regulation of everyone who provides therapy (Section 2).
Many other harms arise from the ordinary exercise of power, which the final part of this section considers.
3.2 Power, Supervision, Documentation and the Practitioner's Inner Work
Power in a dosing session comes from the practitioner's knowledge, role and control of the setting, and from the client's temporary dependence. Ethical practice uses that power to keep the person safe while leaving the meaning of the experience to the person, supported by supervision, documentation and reflective work.
3.2.1 Power and the Non-Directive Stance
Trial models of MDMA-assisted therapy describe the therapy as inner-directed, supporting the participant to approach difficult material without interfering with their spontaneous experience (Mitchell et al., 2021), and Oregon requires facilitators to take a non-directive approach (OAR 333-333-5120). The stance limits a practitioner's influence over a suggestible person. In the practitioners' standard that this course shares, the experience belongs to the client, so practitioners avoid imposing interpretations and avoid promising mystical experiences, which many patients do not have (Lesson 5). Villiger (2024) adds that poorly handled self-disclosure of a practitioner's own psychedelic experiences may alter the dynamics of the relationship.
3.2.2 Supervision and Reporting
Supervision is regular review of a practitioner's work by an experienced colleague and the main way to examine countertransference before it becomes behaviour; Health Canada expects unlicensed trial team members to be directly supervised by a licensed therapist (Health Canada, 2022). Supervision works only when practitioners bring difficult material to it and colleagues report concerns. Oregon's consent form tells clients that licensees have a duty to report misconduct (OAR 333-333-5040), and Case 12.1 shows the cost when a colleague who knew did not report.
3.2.3 Documentation and the Study of Harms
Documentation, including consent forms, session notes, physiological readings, recordings made with consent and adverse event reports, makes accountability possible. Systematic reviews have found adverse events in psychedelic studies often poorly defined, assessed unsystematically and probably underreported: Breeksema et al. (2022) reached this conclusion for clinical treatments with serotonergic psychedelics and MDMA, and Hinkle et al. (2024) found that 16 of 68 studies of classic psychedelics published since 2005 described a systematic approach to assessing adverse events. McNamee et al. (2023) argue that "the understudied therapeutic component of PAT [psychedelic-assisted therapy] presents the most serious risks." Regulated programs can produce such records: Oregon's summary for 2025 reported 5,935 clients, 13 reports of emergency services being contacted and 9 severe adverse reactions (Oregon Health Authority [OHA], 2026), counts that cannot show cause and depend on accurate reporting.
3.2.4 The Practitioner's Own Inner Work
Phelps (2017) listed therapist self-awareness and ethical integrity among six competencies for psychedelic therapists, and Dames et al. (2026) treat the practitioner's way of "being," including relational presence and ethical stance, as a competency alongside technical skill. Inner work includes personal therapy, supervision, reflective practice and attention to burnout, because a practitioner who has not examined their own needs for admiration, closeness or certainty may act on them with a suggestible client. Section 2 asks whether practitioners should have their own psychedelic experiences during training.
Interactive 12.1 applies these principles to four decisions in a hypothetical psilocybin session in an authorized trial; read the feedback for each choice.
The participant is a hypothetical adult enrolled in an authorized psilocybin trial in Canada. The team consists of two therapists, one of them licensed, with a physician on site. Choose a response at each step.
Using Table 12.2 and Figure 12.1, draft a one-page agreement for the participant in Interactive 12.1 that covers (1) the kinds of supportive touch consented to, if any, with a statement that no other kinds will be introduced; (2) a wordless signal for "stop"; (3) who will be present and whether the session will be recorded; (4) the rule on relationships during treatment and for at least one year afterward; (5) how to report a concern independently of the treating team; and (6) when the agreement will be reviewed. Name the source in this section that supports each item.
These safeguards depend on the people who apply them, and Section 2 turns to who may practise in British Columbia, how practitioners are trained, and the debate over experiential training.
Key Takeaways
- 1.1 A dosing session lasts for hours and cannot easily be revisited once the drug is taken, and a small study found that LSD raised suggestibility scores. The altered state also intensifies transference and countertransference and is hard to describe in advance, so each feature weakens a protection that ordinary consent takes for granted. Boundary drift, small steps away from agreed limits, can precede a serious violation.
- 1.2 Marks et al. (2024) identified seven components of consent to psychedelic medicine, including the limited role of touch, the potential for abuse or coercion and practitioner disclosures. Consent to touch, recording and other conditions is obtained while the person is sober, may be withdrawn before the drug is given, and is renewed in integration before any further session. Consent also includes an honest account of the legal route, since a Special Access Program authorization is not a statement that the drug is safe or effective.
- 2.1 Health Canada's 2022 trial expectations require any contact to be non-intimate and non-sexual, with consent for touch obtained before the drug is given, and Oregon's rules, as of October 2026, permit supportive touch only on request with prior written consent, limited to hugs or hands on the client's hands, feet or shoulders. Health Canada's 2022 trial expectations, Oregon's rules and Canadian professional guidance all prohibit sexual contact with clients, and Oregon extends the prohibition to one year after the last service and to the client's partner and family.
- 3.1 In Case 12.1, two providers, recording and supervision were all in place and failed, because one co-therapist did not report the other, the video was reviewed years later, and the sexual relationship began after the active treatment sessions with a therapist who was outside any regulator. The case points toward independence within teams, routine review of recordings, reporting duties for every team member, rules for the period after treatment, and regulation of everyone who provides therapy.
- 3.2 Practitioners hold most of the practical power in a dosing session, so a non-directive stance leaves the meaning of the experience to the client. Supervision examines countertransference before it becomes behaviour and works only when colleagues report concerns, and documentation makes accountability possible, although systematic reviews have found adverse events in trials often poorly defined and probably underreported. The practitioner's own inner work guards against acting on personal needs with a suggestible client.
Reflection
You are the second therapist in a hypothetical authorized psilocybin trial session in Canada. The trial is video-recorded with the participant's consent. In preparation, the participant consented in writing to hand-holding only. Four hours into the session, the lead therapist, who is senior to you, lies down beside the participant and holds them, saying that the participant asked for it. Explain what you would do during the session and afterward, which standards from this section support your actions (name at least two sources), and which safeguard you consider most important in this situation and why.
During the session I would stay in the room, keep my attention on the participant's safety, and calmly ask my colleague to return to the agreed hand-holding, reminding them that the written plan allows only that. If they refused, I would contact the physician on site, because the participant should not be left with a practitioner who is acting outside the plan. I would note the time and what happened. A request made at the peak of a session cannot replace consent given while sober: Health Canada's 2022 expectations state that consent for touch is obtained before the drug is given, and Marks et al. (2024) list the limited role of touch as an essential consent component.
Afterward I would report the event through the trial's reporting procedure to the principal investigator, the sponsor and the ethics board, and ask that the recording be reviewed by someone outside the team. I would make sure the participant could discuss the event in integration with someone other than the lead therapist and knew how to complain independently. The safeguard that matters most here is my own duty to report. In Case 12.1 two therapists, recording and supervision were all in place, MAPS concluded that none were sufficient, and the co-therapist who knew of the misconduct did not report it.
Minimum 20 characters required.
Question 1: Why do Health Canada's 2022 trial expectations and Oregon's rules require consent to touch to be given before the drug is taken?
Question 2: Which of the following is one of the seven components of informed consent to psychedelic medicine identified by Marks et al. (2024)?
Question 3: In Case 12.1, the safeguards in place included two providers at every visit, video recording, monitoring and clinical supervision. Which statement best explains why they failed?
Question 4: Under Oregon's rules for licensed psilocybin facilitators, which of the following is permitted?
Training and Competencies: Professions, Programs and the Experiential Training Debate
Content note. This section refers again to the sexual misconduct described in Case 12.1. If you would like support, VictimLinkBC can be reached by call or text at 1-800-563-0808, the 9-8-8 Suicide Crisis Helpline by call or text at 9-8-8, and the Hope for Wellness Help Line for Indigenous people at 1-855-242-3310.
Introduction
Section 1 showed that the safeguards of psychedelic-assisted therapy rely on the practitioners who apply them. Who those practitioners are, how they are trained and who holds them accountable are therefore ethical questions as much as administrative ones. As of October 2026, Canada had no separate licence for a "psychedelic therapist," so practitioners worked under the rules of their existing professions, and training had grown through university certificates, hospital programs, non-profit organizations and private providers.
The four parts below describe who may provide care on lawful routes in British Columbia, the training programs available as of October 2026, the competencies the field has proposed, and the unresolved debate over whether trainees should have psychedelic experiences of their own.
Learning Objectives
- 4.1 Describe which professionals may prescribe, deliver therapy and monitor patients on lawful psychedelic routes in British Columbia, and how health profession regulation in the province changed in 2026.
- 4.2 Compare Canadian and international training programs by format, length, experiential components and dated status.
- 4.3 Summarize the competency frameworks proposed for psychedelic therapists and relate training activities to them.
- 5.1 Weigh the arguments for and against experiential training and explain the Canadian legal position on it as of October 2026.
4.1 Who May Provide Psychedelic-Assisted Therapy
Psychedelic-assisted therapy combines prescribing, psychotherapy and medical monitoring, and each task is governed differently. The rules come from federal drug law, provincial regulation of health professions and, in some jurisdictions, rules written for psychedelic services themselves.
4.1.1 Prescribers, Therapists and Regulated Professions in British Columbia
As of October 2026, on Canada's lawful routes, the drug is requested or prescribed by a practitioner licensed to prescribe in the province, typically a physician or nurse practitioner; Health Canada's 2023 notice states that the Special Access Program (SAP) may authorize a sale when "the health care practitioner is licensed to prescribe drugs in the province or territory where they practice" (Health Canada, 2023). Since 1 October 2026 the SAP has operated under the Controlled Substances Regulations (SOR/2025-242), which allow a practitioner named in an SAP authorization to administer the drug (Lesson 11). The BC Association of Clinical Counsellors, a professional association, advised registered clinical counsellors in October 2024 that they are not qualified to apply through the SAP, that they should offer psychedelic-related services only to sanctioned clinical trials or programs, and that such work requires training, supervision and a multidisciplinary team (BC Association of Clinical Counsellors [BCACC], 2024).
Regulation of the professions changed in 2026. The Health Professions and Occupations Act replaced the Health Professions Act on 1 April 2026, and under it six regulatory colleges regulate 25 health professions (Government of British Columbia, 2026a). Physicians are regulated by the College of Physicians and Surgeons of BC, nurses and nurse practitioners by the BC College of Nurses and Midwives, and psychologists by the College of Health and Care Professionals of BC, whose list of professions, as of October 2026, showed psychotherapists as joining in 2027; social workers are regulated under a separate act by the British Columbia College of Social Workers (Government of British Columbia, 2026a). The province describes the new act as establishing an oversight office for the colleges, committing to cultural safety and humility, and requiring colleges to publish disciplinary actions in a public registry (Government of British Columbia, 2026b).
4.1.2 Why Regulation Matters for Accountability
A regulatory college can investigate complaints, discipline members and remove a licence, and an association can do far less. Case 12.1 showed the consequence of the gap: the Canadian Broadcasting Corporation reported in 2022 that the therapist at the centre of the case was not a licensed psychologist and that, because British Columbia did not regulate therapists, no official body could investigate his conduct (CBC News, 2022). The planned regulation of psychotherapists would narrow that gap for people who practise psychotherapy in the province.
Jurisdictions that have written rules for psychedelic services take different views of who should deliver them. Table 12.3 compares Health Canada's trial expectations and the trial practice reported in the phase 3 MDMA studies, Alberta's licensing regime (in force 16 January 2023), and Oregon's facilitator model.
Table 12.3. Who delivers psychedelic-assisted care under three models, as of October 2026.
| Model | Prescribing and medical oversight | Who delivers the therapy or support | Training requirement |
|---|---|---|---|
| Clinical trials in Canada (Health Canada, 2022) and the phase 3 MDMA trials (Mitchell et al., 2021) | A physician readily available on site during dosing | At least two therapists present; in the MDMA trials every therapist held a master's degree or higher and one per team was licensed to provide psychotherapy | Trained on evidence-informed protocols; the MDMA sponsor's five-part training |
| Alberta's licensed psychedelic drug treatment services (in force 16 January 2023) | Clinical oversight by a psychiatrist; prescribing by a psychiatrist or a physician consulting one | Psychotherapy by qualified persons set out in the standards; monitoring during altered states | Employee qualifications and training are part of the licensing standards |
| Oregon's licensed psilocybin services (services from 2023) | No diagnosis or medical referral required; services described as non-medical | A licensed facilitator, aged 21 or older with a high school diploma; since 1 January 2026 a facilitator who is also a licensed health professional may, after notifying the state, provide health care in preparation and integration sessions, but not during administration sessions | An approved training program, a state examination and a background check |
Sources: Health Canada (2022); Mitchell et al. (2021, 2023); Government of Alberta (2025); Oregon Health Authority [OHA] (2024); OAR 333-333-5040 and 333-333-5130.
The contrast in Table 12.3 is one form of the policy debate that runs through this course. The course's practice standard favours licensed providers working within regulated professions, as in Alberta and in trials; supporters of Oregon's approach argue that a non-medical model widens access for people without a diagnosis, and Section 3 returns to who actually uses it. With the question of who may practise set out, the next part turns to how practitioners are trained.
4.2 Training Programs in Canada and Elsewhere
Training programs in psychedelic-assisted therapy are new, vary widely, and change quickly. A program that existed when a practitioner enrolled may no longer exist, so the status of each program is given with its date. Table 12.4 summarizes nine programs and standards in Canada and the United States.
Table 12.4. Selected training programs and training standards, with format, experiential components and status as verified in October 2026.
| Program or standard | Format and length | Experiential component | Dated status |
|---|---|---|---|
| Vancouver Island University, Graduate Certificate in Psychedelic-Assisted Therapy (Nanaimo) | One-year graduate certificate; first intake 2022; about 219 students in four cohorts, 2022 to 2025 | Experiential, relational and place-based learning; supervised practicum | Cancelled 20 November 2025; continuing students supported until 31 August 2026 |
| University of Ottawa, MA in Psychedelics and Consciousness Studies | One year online, or two years part-time; for licensed professionals, spiritual care providers, traditional healers and researchers | A specialized training component for mental health and spiritual care professionals | Announced 29 May 2024; first intake September 2024 |
| Michener Institute of Education at UHN, Foundations of Psychedelic Psychotherapy (Toronto) | About 100 hours: recorded lectures, weekly live virtual sessions, a virtual weekend and a five-day in-person retreat; launched September 2022 | Holotropic breathwork at the retreat; role-plays; apprenticeship as a co-therapist | Latest application deadline found: 1 November 2024 |
| MAPS Canada School of Psychedelics (online) | Launched 3 May 2023 with a seven-part seminar series | None described | Still listed on the MAPS Canada website; course platform showed an inactive account on 17 October 2026 |
| TheraPsil (Victoria) | Five-day psilocybin course, six-day MDMA course and an online psilocybin course | An "Experiential Training" program is listed without detail | Cohorts listed for October 2026 to January 2027 |
| Roots to Thrive (Nanaimo) | Experiential Intensive Training (52 hours); Preceptor Training (12 weeks, about 90 hours) | An experiential ketamine-assisted therapy training is listed; content not described on the home page | Cohort listed for November 2026 |
| California Institute of Integral Studies, Certificate in Psychedelic-Assisted Therapies and Research (San Francisco) | 12 months; 140 to 150 hours over eight weekends; centre created 2015 | Not specified on the program page | 2026 to 2027 cohort closed; next applications open 15 January 2027 |
| Oregon minimum for approved facilitator training | At least 128 hours of core instruction and at least 40 hours of practicum | Up to 4 practicum hours may be credited for taking part as a client | In force from 1 January 2025 |
| MAPS sponsor training for the phase 3 MDMA trials | Online course (15 hours), five-day course, role play (1 day) and supervision (52 hours) | Three days of experiential learning | As reported for the first phase 3 trial (Mitchell et al., 2021) |
Sources: Vancouver Island University (2025); Dames et al. (2026); University of Ottawa (2024); Michener Institute (2024); University Health Network (n.d.); Mugglehead (2023); MAPS Canada (2026); TheraPsil (2026); Roots to Thrive (2026); California Institute of Integral Studies (2026); OAR 333-333-3050 and 333-333-3070; Mitchell et al. (2021).
4.2.1 The Canadian Programs
The Canadian programs differ in purpose. Vancouver Island University's certificate was taught by faculty who also work with Roots to Thrive, and its four cohorts were used to refine a competency framework through a quality improvement process (Dames et al., 2026). The University of Ottawa's master's degree combines psychology with religious studies and admits clergy and traditional healers as well as clinicians, which reflects a view that spiritual guidance belongs in psychedelic care (University of Ottawa, 2024). The Michener program's applicants must acknowledge that "standards and regulations for psychedelic psychotherapy do not currently exist in Canada" (Michener Institute, 2024). TheraPsil and Roots to Thrive are non-profit organizations that train practitioners alongside their clinical or advocacy work, and MAPS Canada's online school is an educational offering whose status could not be confirmed in October 2026.
4.2.2 International Standards
As of October 2026, Oregon set a minimum curriculum for facilitator training by rule. Its core training includes 12 hours each on historical and traditional practices, cultural equity, and safety and ethics, alongside modules on facilitation skills, preparation, administration, integration and group facilitation (OAR 333-333-3050), and its practicum must include at least 30 hours of direct practice and 10 hours of consultation (OAR 333-333-3070). Trial sponsors set their own requirements, as the MAPS training for the MDMA trials shows (Mitchell et al., 2021).
Figure 12.2 places the Canadian training and regulatory events of 2019 to 2027 on a single timeline, so that the rise and contraction of programs can be read alongside the legal decisions that shaped them.
Programs teach different things for different lengths of time, so the field has tried to say what a competent practitioner should be able to do regardless of where they trained. The next part describes those attempts.
4.3 Core Competencies
A competency is a combination of knowledge, skill and judgement that can be observed in practice. Competency frameworks matter because, as of October 2026, no accreditation body for psychedelic training in Canada had been identified, and programs had no shared standard against which they could be compared.
4.3.1 Phelps's Six Competencies
Janis Phelps of the California Institute of Integral Studies published a review and compilation of psychedelic therapist competencies drawn from the literature (Phelps, 2017). She identified six: empathetic abiding presence; trust enhancement; spiritual intelligence; knowledge of the physical and psychological effects of psychedelics; therapist self-awareness and ethical integrity; and proficiency in complementary techniques. She also described twelve curricular domains for developing them. The framework is a synthesis of published writing, so it records what experienced practitioners considered necessary.
4.3.2 Frameworks since 2022
Later frameworks include one developed at Vancouver Island University, which adds culture, regulation and equity. It centres on "doing" (technical and clinical practice) and "being" (relational presence and ethical stance), operationalized in five domains and supported by a program code of ethics; its authors describe it as a locally adaptable design developed through quality improvement, without external validation (Dames et al., 2026). A model curriculum written by an international group of experienced clinicians proposes apprenticeship observation, ongoing clinical supervision and self-experience for trainees, and notes that a government-approved curriculum in Czechoslovakia once required five controlled self-experiences and 30 supervised LSD sessions with five patients (Passie et al., 2026). The tabs below summarize four frameworks that a British Columbia practitioner might consult.
Six competencies: empathetic abiding presence; trust enhancement; spiritual intelligence; knowledge of the physical and psychological effects of psychedelics; therapist self-awareness and ethical integrity; proficiency in complementary techniques. Twelve curricular domains support their development.
Five domains: therapeutic presence and trustworthiness; culture and identity; historical, political and regulatory literacy; evidence-informed clinical knowledge; and a trauma-informed and equity-informed process spanning screening, preparation, consent, team roles and integration. A program code addresses safety, confidentiality, equity, competence, power and boundaries, including touch.
At least 128 hours of core instruction, including 12 hours each on historical and traditional practices, cultural equity, safety and ethics, and pharmacology and research; 16 hours each on facilitation skills, preparation and group facilitation; 20 hours on administration; 12 hours on integration; and at least 40 hours of practicum (OAR 333-333-3050 and 333-333-3070).
Training linked to educational institutions or multi-professional teams that covers theory, the science of psychedelics, history, research ethics, ethical conduct across professions, informed consent, standards of practice, federal and provincial regulation, risk management, a supervised practicum, and Indigenous and cultural connections to ceremonial uses of plants.
Interactive 12.2 asks you to match eight training activities to Phelps's six competencies. Several activities develop more than one competency, so the feedback names the closest fit and explains the reasoning.
For each activity, choose the competency from Phelps (2017) that it develops most directly.
Most of the activities in Interactive 12.2 can be taught through lectures, role-play and supervised practice. One cannot be taught that way, at least in the view of many trainers, and it is the subject of the final part of this section.
5.1 The Debate over Experiential Training
Experiential training, in this context, means a trainee's own experience of a psychedelic or of another non-ordinary state of consciousness as part of professional preparation. Villiger (2024) describes personal psychedelic experience as common among psychedelic therapists and cites a survey of therapists in a phase 2 psilocybin trial in which 88 percent of those who responded, about one fifth of those invited, had taken a psychedelic at least once (Aday et al., 2023); with so few responding, the figure may not describe all the therapists invited. Whether it should be part of formal training is contested.
5.1.1 Arguments for Experiential Training
Dames et al. (2024), educators in the Vancouver Island University program, argue that first-hand experience helps practitioners understand non-ordinary states, builds the confidence to stay present when a session becomes difficult, and can support the trainee's own mental health. They also argue that legal barriers push trainees toward underground experiences, so offering experiential training in regulated settings could make it safer and more accountable. They acknowledge that these arguments "remain anecdotal and open to criticism."
5.1.2 Arguments against Requiring It
Villiger (2024) examined the question from an ethics perspective and found no evidence that a therapist's personal psychedelic experience improves therapeutic effects or reduces harms, and no conclusive evidence that therapists' personal experience of the disorder being treated, or of psychotherapy, improves outcomes. He concludes that the evidence does not justify a requirement, and that because the experience may be valuable and the likelihood of harm in screened people is low, trainees should be given a legal opportunity to have one. A requirement would also exclude people for whom psychedelics are medically contraindicated, which is one reason some authors propose familiarity with non-drug altered states such as breathwork (Villiger, 2024). Dames et al. (2024) list further counterarguments, including that a therapist's personal knowledge of addiction does not consistently predict better outcomes and that personal enthusiasm may bias practitioners and researchers. Evidence on both sides is limited, and research on training is evolving.
5.1.3 The Legal Position in Canada
In Canada the question has been decided case by case under section 56 of the Controlled Drugs and Substances Act. In December 2020 the Minister of Health granted exemptions allowing health care practitioners to possess and consume psilocybin in TheraPsil's training program, 19 in total that year. In June 2022 the Minister refused further requests; the Federal Court dismissed the practitioners' challenge on 25 September 2023, and on 18 June 2025 the Federal Court of Appeal allowed their appeal, finding that the Minister had not explained the departure from the 2020 approvals, and returned the requests of the 73 practitioners who appealed to the Minister for redetermination (Toth v. Canada, 2025 FCA 119). No public outcome of that redetermination had been found as of October 2026. Programs have used lawful alternatives, including holotropic breathwork (Michener Institute, 2024) and participation as a client in a licensed session, which Oregon credits toward practicum hours (OAR 333-333-3070). The course's position is that experiential training, where offered, must stay within authorized routes.
The four positions taken in the literature are summarized below. Open each to read its main argument and its main weakness.
Supporters argue that only first-hand experience gives a practitioner a felt understanding of the states clients enter, and some historical curricula required it (Passie et al., 2026). Its weakness is that a 2024 review found no evidence that personal psychedelic experience improves outcomes, so the evidence does not support a requirement, and a requirement would exclude trainees with medical contraindications (Villiger, 2024).
Trainees who wish to may have a screened experience within an authorized program, as the 2020 exemptions allowed. This is the position Villiger (2024) reaches. Its weakness in Canada is that, as of October 2026, lawful access depended on ministerial exemptions that had been granted, refused and litigated.
Some argue that personal use may bias practitioners and that training should rest on supervision and evidence. Its weakness is that it leaves trainees who seek experience to underground sources, the concern raised by Dames et al. (2024).
A hypothetical registered nurse in British Columbia wants to join a team that delivers psilocybin-assisted therapy through Special Access Program requests. Using Tables 12.3 and 12.4, choose two programs that were open to applicants in October 2026 and compare them on (1) total hours and supervised practice, (2) coverage of Phelps's six competencies and the five domains of Dames et al. (2026), (3) ethics content on touch, boundaries and power, (4) cultural safety and Indigenous content, and (5) any experiential component and its legal basis. State which program you would recommend, what training would still be missing for the nurse's role on the team, and which professional college would hold the nurse accountable.
Training and regulation determine who provides care. They do not determine who receives it, whose knowledge it draws on, or who can afford it. Section 3 turns to those questions: Indigenous knowledge and reciprocity, the diversity of trial participants, and the cost of psychedelic-assisted therapy.
Key Takeaways
- 4.1 As of October 2026, on Canada's lawful routes a practitioner licensed to prescribe, typically a physician or nurse practitioner, requests or prescribes the drug, and the BC Association of Clinical Counsellors advised in October 2024 that counsellors offer psychedelic-related services only to sanctioned trials or programs. In British Columbia, the Health Professions and Occupations Act replaced the Health Professions Act on 1 April 2026, and, as of October 2026, psychotherapists were listed to join a regulatory college in 2027, which would narrow the accountability gap that Case 12.1 exposed. Canadian trials, Alberta and Oregon take different views of who should deliver care.
- 4.2 Canadian training changed quickly: Vancouver Island University cancelled its certificate on 20 November 2025, the University of Ottawa's master's degree began in 2024, the latest Michener deadline found was November 2024, and the MAPS Canada school's platform status was uncertain in October 2026. As of October 2026, Oregon set a minimum curriculum for facilitator training by rule, with at least 128 hours of core instruction and 40 hours of practicum.
- 4.3 Phelps (2017) identified six competencies for psychedelic therapists, from empathetic abiding presence to proficiency in complementary techniques. Later frameworks include the Vancouver Island University framework of "doing" and "being" in five domains, which adds culture, regulation and equity, although, as of October 2026, no accreditation body for psychedelic training in Canada had been identified, and programs had no shared standard against which they could be compared.
- 5.1 A 2024 review found no evidence that therapists' personal psychedelic experience improves outcomes; its supporters acknowledge that their arguments remain anecdotal, and Villiger (2024) concluded that it should be a lawful option rather than a requirement. In Canada, as of October 2026, lawful experiential training had depended on ministerial exemptions that had been granted, refused and litigated, most recently in Toth v. Canada (2025 FCA 119), and programs have used lawful alternatives such as breathwork.
Reflection
A hypothetical registered clinical counsellor in British Columbia wants to work in psilocybin-assisted therapy and is choosing between two plans. Plan A: complete a training program that includes supervised practice and a holotropic breathwork retreat, then join a team in which a physician makes Special Access Program requests and the counsellor provides preparation and integration under supervision. Plan B: attend a retreat abroad to have a personal psilocybin experience, then offer preparation and integration sessions to clients who obtain psilocybin themselves. Using this section, explain which plan is consistent with the Canadian legal position and the October 2024 guidance of the BC Association of Clinical Counsellors, what the evidence says about the value of personal psychedelic experience, and what British Columbia's planned regulation of psychotherapists from 2027 might change for this counsellor.
Plan A is consistent with the law and the professional guidance. The counsellor would work on a lawful route, with a prescribing physician making Special Access Program requests, and the BC Association of Clinical Counsellors advised in October 2024 that counsellors should offer psychedelic-related services only to sanctioned trials or programs, with training, supervision and a multidisciplinary team. Plan B fails on two counts. Preparing and integrating clients who use psilocybin they obtain themselves is the kind of support for unauthorized use that Lesson 7 identified as a legal risk for regulated professionals, and the counsellor would be working outside any sanctioned program.
The personal experience in Plan B also has weaker support than its advocates suggest. Dames et al. (2024) argue that first-hand experience builds understanding and confidence, but they acknowledge that their arguments remain anecdotal, and Villiger (2024) found no evidence that a therapist's personal psychedelic experience improves outcomes. Breathwork offers a lawful way to experience a non-ordinary state, although it may not resemble a specific drug closely. If psychotherapists join the College of Health and Care Professionals of BC in 2027 as planned, the counsellor would become accountable to a regulator that can investigate complaints and discipline members, which would narrow the gap that Case 12.1 exposed.
Minimum 20 characters required.
Question 1: As of October 2026, which statement about Vancouver Island University's Graduate Certificate in Psychedelic-Assisted Therapy is correct?
Question 2: Which pair lists two of the six competencies identified by Phelps (2017)?
Question 3: What did the Federal Court of Appeal decide in Toth v. Canada (2025 FCA 119) on 18 June 2025?
Question 4: What did Villiger (2024) conclude about therapists' personal psychedelic experience during training?
Indigenous Knowledge, Reciprocity and Equity of Access
Introduction
Lesson 2 described the Indigenous and ceremonial traditions in which several psychedelics were used long before Western psychiatry encountered them, their colonial suppression, and the harm that outside attention brought to María Sabina's Mazatec community. This section asks what those histories require of psychedelic practice now, and then turns to two further questions of fairness: who has been studied in trials, and who can afford treatment. The course draws on Indigenous-authored sources where possible. HSCI 8XX develops Indigenous research ethics in depth, and HSCI 214 develops structural inequity and the colonial determinants of health.
Learning Objectives
- 6.1 Describe the eight ethical principles of traditional Indigenous medicine proposed for Western psychedelic research and practice, and give an example of how a service in British Columbia might act on each.
- 6.2 Explain Two-Eyed Seeing and the caution its originators give about using it as a label.
- 6.3 Describe Calls to Action 22 and 24, the relevant articles of the United Nations Declaration on the Rights of Indigenous Peoples and British Columbia's Declaration Act, and explain why cultural safety is a condition of ethical practice.
- 6.4 Describe the Nagoya Protocol and Canada's status under it, and explain concerns about overharvesting of sacred plants.
- 7.1 Compare the ethnoracial composition of earlier psychedelic studies with that of a recent phase 3 trial, and explain why representation matters for the evidence.
- 7.2 Use Calculator 12.1 to estimate clinician time and cost for a course of psychedelic-assisted therapy, and relate the result to public funding and equity of access.
6.1 Indigenous Knowledge and the Ethics of Reciprocity
Reciprocity means a relationship in which benefits and obligations flow in both directions. Indigenous scholars and others have argued that Western psychedelic science has taken knowledge, plants and practices from Indigenous communities while returning little, and that ethical practice requires changing that relationship (Celidwen et al., 2023; George et al., 2019).
Celidwen et al. (2023) report a consensus process held between October 2021 and March 2022 by an Indigenous-led, globally represented group of practitioners, activists, scholars, lawyers and human rights defenders. The group identified eight interconnected principles in four categories: Acknowledgement (Reverence and Respect), Knowledge Translation and Education (Responsibility and Relevance), Intellectual Property (Regulation and Reparation), and Belonging (Restoration and Reconciliation). Free, prior and informed consent, the right of a community to give or withhold consent before its knowledge is used, is central to several of them. Table 12.5 summarizes each principle and adds an example, written for this lesson, of how a psychedelic service in British Columbia might act on it.
Table 12.5. The eight ethical principles of Celidwen et al. (2023), what each asks of Western research and practice, and an illustrative action for a service in British Columbia.
| Category and principle | What the principle asks (paraphrased from Celidwen et al., 2023) | Illustrative action for a British Columbia service |
|---|---|---|
| Acknowledgement: Reverence | Acknowledge Indigenous medicine systems as the root of Western psychedelic practice, and support protection of the lands where the medicines originate. | State the Indigenous origins of the practices in service materials, with wording guided by local Indigenous scholars. |
| Acknowledgement: Respect | Build relationships first, follow regional protocols, and obtain free, prior and informed consent before using Indigenous knowledge in new contexts. | Use no ceremonial elements unless the communities concerned have agreed and take part on their own terms. |
| Knowledge translation: Responsibility | Hold institutions accountable for appropriation and for profiting from Indigenous practices without consent. | Include Indigenous members in the ethics review of the service's research and programs. |
| Knowledge translation: Relevance | Bring Indigenous leadership and methodologies into Western education, research and practice. | Fund Indigenous leadership roles in training and evaluation. |
| Intellectual property: Regulation | Develop legal protection of traditional medicine knowledge grounded in Indigenous self-determined law. | Make no claim of ownership over traditional knowledge or practices. |
| Intellectual property: Reparation | Share benefits fairly with the communities whose knowledge or resources are used, including reparation where they were taken without consent. | Agree any benefit sharing with communities, on their terms. |
| Belonging: Restoration | Restore Indigenous authority as the guiding voice in the development of traditional medicines and practices. | Follow the direction of Indigenous partners on anything involving traditional medicines. |
| Belonging: Reconciliation | Cooperate locally, nationally and internationally on restorative and transformative justice in Indigenous and Western relations. | Align the service with the Calls to Action and British Columbia's Declaration Act, described below. |
The principles ask more than good intentions. Several describe structural obligations, such as funding Indigenous-led ethical review bodies and supporting community protocols, that a single service cannot meet alone (Celidwen et al., 2023). The next framework, developed in Canada, describes how two knowledge systems can work together.
6.2 Two-Eyed Seeing
Etuaptmumk, or Two-Eyed Seeing, is a guiding principle brought to academic work by Mi'kmaw Elders Albert and Murdena Marshall of Eskasoni First Nation and Cheryl Bartlett, through the Integrative Science program at Cape Breton University (Bartlett, Marshall & Marshall, 2012). Its originators describe it as "learning to see from one eye with the strengths of Indigenous knowledges and ways of knowing, and from the other eye with the strengths of Western knowledges and ways of knowing ... and learning to use both these eyes together, for the benefit of all" (quoted in Roher et al., 2024). Elder Albert Marshall has warned that such work "can all too easily slip into a lazy, tokenistic approach" in which the term becomes "mere jargon, trivialized, romanticized, co-opted, or used as a 'mechanism'" (quoted in Roher et al., 2024). Figure 12.3 represents the idea as a teaching diagram.
6.3 Commitments in Canada and British Columbia
Canadian and provincial commitments give these principles practical weight. The Truth and Reconciliation Commission's Call to Action 22 (2015) asks those who can effect change in the health care system "to recognize the value of Aboriginal healing practices and use them in the treatment of Aboriginal patients in collaboration with Aboriginal healers and Elders where requested by Aboriginal patients," and Call to Action 24 asks medical and nursing schools to teach Aboriginal health issues with skills-based training in intercultural competency and anti-racism (Truth and Reconciliation Commission of Canada, 2015). The United Nations Declaration on the Rights of Indigenous Peoples recognizes Indigenous peoples' right to their traditional medicines and health practices, including conservation of medicinal plants (Article 24), and their right to maintain, control, protect and develop their traditional knowledge, including medicines and knowledge of the properties of plants, and their intellectual property over it (Article 31). British Columbia's Declaration on the Rights of Indigenous Peoples Act (assented to 28 November 2019) requires the province, in consultation and cooperation with Indigenous peoples, to take all measures necessary to make its laws consistent with the Declaration (section 3).
The province's own review of health care, In Plain Sight (November 2020), heard from almost 9,000 people and found widespread systemic racism against Indigenous peoples in British Columbia's health care system; among Indigenous respondents to its survey, 26 percent said they were always assumed to be drunk or asked about substance use (Turpel-Lafond, 2020). A psychedelic service that operates in that system inherits its history, which is why cultural safety, meaning care that Indigenous people themselves experience as safe and free of racism, is a condition of ethical practice. These commitments concern relationships and knowledge. The plants themselves raise a further set of obligations, described next.
6.4 Benefit Sharing, the Nagoya Protocol and Sacred Plants
Benefit sharing is the principle that those who provide genetic resources or traditional knowledge should share fairly in the benefits of their use. It is written into international law through an agreement under the Convention on Biological Diversity, summarized below.
The Nagoya Protocol at a glance (October 2026)
The Nagoya Protocol on Access and Benefit-sharing was adopted on 29 October 2010 in Nagoya, Japan, and entered into force on 12 October 2014. Its objective is the fair and equitable sharing of benefits arising from the use of genetic resources (Secretariat of the Convention on Biological Diversity [SCBD], 2015). In October 2026 the Protocol had 143 Parties, including Mexico, Peru, Ecuador, Brazil and Gabon; Canada and the United States were not Parties, and Canada had not signed it (SCBD, n.d.). Celidwen et al. (2023) note that these frameworks do not reach research and practice in countries that are not Parties.
Celidwen et al. (2023) report that unsustainable foraging of Indigenous medicines is making them increasingly unavailable for local use, and they connect psychedelic tourism and spiritual consumerism to harms on Indigenous lands. A 2026 commentary by an international group that includes Sandor Iron Rope, a Lakota ceremonial leader and founding board member of the Indigenous Peyote Conservation Initiative, argues that decriminalizing or legalizing "sacred plant medicines" would reduce criminal penalties faced by Indigenous peoples and could also lead to environmental degradation and overharvesting of sacred plants (Magar et al., 2026). The same commentary points to clinical research on ibogaine, derived from Tabernanthe iboga and central to the Bwiti tradition of Gabon and Cameroon, as an example of research that has drawn on a ceremonial medicine while its originators remained marginal to the science. For practitioners outside these traditions, the implication is restraint: Western services use synthetic or regulated products through lawful routes, and these plants and ceremonies remain under the authority of the communities whose practices they are.
Questions of who benefits also apply to the people who take part in research. The next part examines who has been studied.
7.1 Who Is Studied: Diversity in Psychedelic Trials
A trial's results apply most confidently to people like those who took part. When participants come mainly from one group, the evidence may not generalize, and the treatment may be shaped around one group's expectations and cultural frame (George et al., 2019).
Michaels et al. (2018) reviewed psychedelic studies published between 1993 and 2017 and found that most participants were non-Hispanic White. A 2024 systematic review found that non-Hispanic White participants remained an over-represented majority by a large margin in studies published after 2017, although studies in the United States included larger shares of minoritized groups than before (Hughes & Garcia-Romeu, 2024). One trial, MAPP2 (the second phase 3 trial of MDMA-assisted therapy for post-traumatic stress disorder, which recruited between August 2020 and May 2022), reported a more diverse sample (Mitchell et al., 2023). Table 12.6 compares the earlier review with that trial. Its categories differ between sources and are reproduced as published, so comparisons are approximate, and research on representation is evolving.
Table 12.6. Ethnoracial composition of participants in psychedelic studies from 1993 to 2017 and in the MAPP2 trial, as reported by the authors.
| Measure | Michaels et al. (2018), 18 studies, 1993 to 2017 | MAPP2 (Mitchell et al., 2023) |
|---|---|---|
| Participants | 282 | 104 randomized |
| White | 82.3 percent non-Hispanic White | 66.3 percent (33.7 percent identified as other than White) |
| Hispanic or Latino | 2.1 percent of Latino origin | 26.9 percent |
| Other groups reported | African American 2.5 percent; Asian 1.8 percent; Indigenous 4.6 percent; mixed 4.6 percent; other 1.8 percent; unknown 8.2 percent | Not broken down in the abstract |
Sources: Michaels et al. (2018); Mitchell et al. (2023). The published percentages for Michaels et al. (2018) total more than 100, presumably because some categories overlap; they are reproduced as published.
Michaels et al. (2018) found no significant differences in recruitment methods between studies with higher and lower inclusion, and they concluded that improved recruitment strategies are needed. Williams and Labate (2019) add that people of colour and women were uncommon in leadership positions in psychedelic research. Lesson 6 described exclusion criteria, such as family histories of psychosis, which also shape who can take part. Representation determines what the evidence can say. Cost determines who benefits once a treatment exists, and it is the subject of the final part of this section.
7.2 Cost, Public Funding and Equity of Access
Williams and Labate (2019) observed that the models of psychedelic psychotherapy used in trials are resource-intensive and therefore likely to remain out of reach for people who are socioeconomically disadvantaged if they are approved as medical treatments. Much of that cost is clinician time.
7.2.1 Estimating Clinician Time and Cost
The phase 3 MDMA trials used three 90-minute preparation sessions with a two-person therapy team, three dosing sessions of about eight hours, and nine 90-minute integration sessions (Mitchell et al., 2021, 2023). The formula below converts a schedule like this into clinician hours and cost per participant, and multiplies the extra cost over the comparison by the number needed to treat (Lesson 8) to estimate the cost of one additional good outcome.
Worked Example 12.1: The MAPP schedule with hypothetical costs
Preparation: P = 3 × 1.5 = 4.5 hours. Dosing: D = 3 × 8 = 24 hours. Integration: I = 9 × 1.5 = 13.5 hours. With the same two-person team in every session, as the treatment manual describes (Lesson 9), and one participant per session, h = (4.5 + 24 + 13.5) × 2 ÷ 1 = 84 clinician hours.
Using a hypothetical cost of $150 per clinician hour and hypothetical other costs of $2,000 per participant, C = 84 × 150 + 2,000 = $14,600.
MAPP2 reported that 71.2 percent of the MDMA group and 47.6 percent of the placebo-with-therapy group no longer met criteria for post-traumatic stress disorder, and the authors reported a number needed to treat of four for this outcome (Mitchell et al., 2023). Because the comparison group received the same therapy hours with a placebo, the number needed to treat describes the added effect of MDMA, and C0 includes the same clinician time. If the hypothetical other costs of $2,000 were entirely the cost of the drug, C0 = 84 × 150 = $12,600, and the cost per additional person who no longer meets criteria is ($14,600 − $12,600) × 4 = $8,000. Multiplying the full course cost ($14,600 × 4 = $58,400) would apply only against a comparison that cost nothing.
Use Calculator 12.1 to change the schedule, team size, group size and costs. The presets include the worked example, the same schedule with a number needed to treat of about 3 (computed from MAPP1, in which 28 of 42 participants given MDMA and 12 of 37 given placebo no longer met criteria; Mitchell et al., 2021) and two hypothetical schedules; watch how group delivery and the number of clinicians change the cost per participant.
7.2.2 Who Pays, in Canada and Elsewhere
No psilocybin or MDMA product had Canadian market authorization in October 2026, so neither could be listed on a drug plan as an approved treatment. Health Canada's notice on SAP requests describes authorizing a manufacturer to sell a drug to a practitioner and does not address payment (Health Canada, 2023). In the Czech Republic, where medical psilocybin became legal on 1 January 2026, the National Institute of Mental Health stated on 23 March 2026 that treatment had not yet started because reimbursement conditions were still being defined, with the aim of integrating this "demanding form of care" into public health insurance, and that the launch was expected in the second half of 2026 (National Institute of Mental Health, Czech Republic, 2026).
Oregon's licensed services are defined as non-medical, and the state's data show who has used them. Of the clients in 2025 who reported household income, most reported incomes above $95,375 (United States dollars), and of those whose place of residence was reported, about 61 percent lived elsewhere in the United States or abroad (OHA, 2026). Counts for small Oregon counties were suppressed for confidentiality, so the true out-of-state share is somewhat lower, and of the 3,785 clients who gave any response to the income question, 960, about a quarter, declined to report income. Figure 12.4 shows the reported income distribution. Oregon offers a reduced annual facilitator licence fee to veterans and to people receiving certain public benefits and requires a social equity plan with each licence application (OHA, 2024), measures aimed at providers more than at clients.
Need and ability to pay often diverge. In a community-based cohort of marginalized women in Metro Vancouver, 43 percent of 486 eligible participants said they were interested in receiving psychedelic-assisted therapy, and interest was associated with lifetime mental health conditions, childhood abuse and daily methamphetamine use (Argento et al., 2022). The authors concluded that any approach extending psychedelic medicine to marginalized women should integrate trauma-informed care and broader social and structural supports.
7.2.3 Weighing Models of Access
The course's practice standard prefers a regulated public health model of access, with licensed providers, training standards and public or charitable funding, to commercialization without standards. Group delivery, as in Roots to Thrive's community-of-practice programs, is one way to reduce clinician hours per participant, although, as of October 2026, its published evaluations were uncontrolled or non-randomized studies, mainly of health care workers (Lesson 10). The counter-arguments deserve equal attention. A medical model requires a diagnosis and specialist time, which may slow access and concentrate it in cities; Oregon's non-medical model needs no diagnosis or referral, although Figure 12.4 shows that most of its clients who reported income had household incomes above $95,375. Noorani (2020) argues that the cost of gaining regulatory approval creates incentives for "diluted-yet-profitable" forms of treatment, while Smith and Appelbaum (2021) warn that commercialization after legalization may give vulnerable people unprecedented access to these substances and that marketing not based on evidence may supplant evidence-based practice. Section 4 develops the commercial side of this debate.
Using Calculator 12.1, compute the clinician hours and cost per participant for (1) the worked example, (2) the hypothetical group schedule preset and (3) a schedule of your own design for ketamine-assisted psychotherapy, stating every assumption and labelling all costs as hypothetical. For each, write one sentence on who could afford it if paid privately and one on what public or charitable funding would need to cover. Then use Figure 12.4 to describe in two sentences whom Oregon's model has mostly reached, and name one design change that would reach people like the participants in Argento et al. (2022).
Questions of cost lead directly to the commercial organizations that have tried to build businesses around psychedelic treatment. Section 4 examines patents, investors, the rise and failure of clinic chains, marketing claims and the future of the field, and ends with the course's integrative task.
Key Takeaways
- 6.1 Celidwen et al. (2023) set out eight ethical principles of traditional Indigenous medicine in four categories: Acknowledgement, Knowledge Translation and Education, Intellectual Property, and Belonging. They ask services to follow Indigenous direction, to use no ceremony or knowledge without free, prior and informed consent, and to share benefits, and several describe structural obligations that a single service cannot meet alone.
- 6.2 Two-Eyed Seeing, brought to academic work by Mi'kmaw Elders Albert and Murdena Marshall and Cheryl Bartlett, means learning to use the strengths of Indigenous and Western knowledges together for the benefit of all. Elder Albert Marshall has warned that the term can slip into a tokenistic approach in which it becomes mere jargon.
- 6.3 Call to Action 22 asks the health care system to recognize the value of Aboriginal healing practices in collaboration with healers and Elders, Articles 24 and 31 of the Declaration recognize rights to traditional medicines and knowledge, and the Declaration Act requires British Columbia to make its laws consistent with the Declaration. In Plain Sight (2020) found widespread systemic racism against Indigenous peoples in the province's health care, so cultural safety is a condition of ethical practice for any psychedelic service.
- 6.4 The Nagoya Protocol, in force since 12 October 2014, seeks fair and equitable sharing of the benefits of genetic resources, but in October 2026 Canada and the United States were not Parties and Canada had not signed it. Legalizing sacred plant medicines could lead to overharvesting, so Western services use synthetic or regulated products through lawful routes and leave these plants and ceremonies under the authority of their communities.
- 7.1 Michaels et al. (2018) found that 82.3 percent of participants in psychedelic studies from 1993 to 2017 were non-Hispanic White, while MAPP2 reported a more diverse sample, with 26.9 percent Hispanic or Latino. Representation determines what the evidence can say, because results apply most confidently to people like those who took part.
- 7.2 Clinician time drives the cost of psychedelic-assisted therapy: the MAPP schedule requires 84 clinician hours per participant, about $14,600 under hypothetical costs. No psilocybin or MDMA product could be listed on a Canadian drug plan in October 2026, and Oregon's 2025 data show that its privately paid services mostly reached clients with higher household incomes, among those who reported income, while many marginalized women in Metro Vancouver reported interest in the therapy.
Reflection
A hypothetical British Columbia service plans to charge each patient the full cost of a course of psilocybin-assisted therapy, which it estimates at 14,600 dollars using a schedule like the MAPP trials (84 clinician hours at a hypothetical 150 dollars an hour, plus 2,000 dollars of other costs). In Oregon's licensed services in 2025, 58.5 percent of the 2,825 clients who reported household income reported more than 95,375 US dollars. In a Metro Vancouver cohort of 486 marginalized women, 43 percent said they were interested in receiving psychedelic-assisted therapy. The service also plans to describe itself as honouring Indigenous traditions. Explain whom this pricing is likely to reach, propose two changes that would improve equity of access and say what each would cost or require, and explain how the service should act on the principles of Celidwen et al. (2023) before saying anything about Indigenous traditions.
Charging 14,600 dollars per course would mostly reach people with high incomes. Oregon's experience suggests this: most clients who reported income earned more than 95,375 US dollars, and many travelled from outside the state. The women in the Metro Vancouver cohort, many of whom are interested in this treatment and have the mental health needs it targets, could not pay that price.
Two changes would help. First, the service could seek public or charitable funding and offer a sliding scale, which requires a funder willing to pay for treatments that are not yet authorized and an evaluation plan that would justify continued funding. Second, where the evidence supports it, it could offer group sessions; Calculator 12.1 shows that three clinicians with six participants reduce clinician hours per participant from 84 to 18 for the hypothetical group schedule, although group delivery changes the therapy and needs its own evaluation.
Before saying anything about Indigenous traditions, the service should build relationships with local First Nations and Indigenous health organizations and follow their direction. Under the principles of Respect and Restoration, it should use no ceremony or traditional knowledge without free, prior and informed consent, and any acknowledgement should be worded with Indigenous partners. Describing itself as honouring traditions without that relationship would be the kind of appropriation the principles describe.
Minimum 20 characters required.
Question 1: Into which four categories did Celidwen et al. (2023) group their eight ethical principles of traditional Indigenous medicine?
Question 2: What was Canada's status under the Nagoya Protocol on Access and Benefit-sharing in October 2026?
Question 3: Using the MAPP trial schedule (4.5 preparation hours, 24 dosing-session hours and 13.5 integration hours), two clinicians in every session and one participant, how many clinician hours are needed per participant?
Question 4: What did Michaels et al. (2018) find in their review of psychedelic studies published from 1993 to 2017?
Commercialization, the Future of the Field and Designing a Responsible Service
Introduction
Psychedelic medicine is being built partly by public researchers and non-profit organizations and partly by companies that need to earn returns for investors. Companies have paid for large trials, such as the phase 3 psilocybin program of Compass Pathways, and they have also brought pressures that Section 3 began to describe. The course's position is that commercialization without standards is the model to avoid; this section sets out the evidence for and against that position so that it can be weighed. It covers patents and investors, the rise and failure of commercial clinic chains, marketing claims, and the field's future, and it ends with the course's integrative task.
Learning Objectives
- 8.1 Describe how patents and investor financing shape the development of psychedelic medicines, using dated company disclosures.
- 8.2 Describe the rise and failure of the Field Trip clinic chain and what the case suggests about commercial models of psychedelic care.
- 8.3 Identify the marketing claims that Canadian law and Oregon's rules restrict, and evaluate example claims against them.
- 8.4 Explain where non-hallucinogenic analogues fit in the field's future and name the main items on a research agenda.
- 9.1 Design a responsible psychedelic service in British Columbia that integrates the evidence, the lawful access routes, and the ethics and equity principles of this course.
8.1 Patents, Investors and the Shape of a Medicine
A patent gives its owner the exclusive right to make, use or sell an invention for a limited period, usually 20 years from filing, in return for public disclosure. Psilocybin itself was isolated by a team at Sandoz in 1958 (Lesson 2), so patents in this field claim particular forms, formulations, manufacturing methods and methods of treatment.
8.1.1 Patents on Forms and Methods
Compass Pathways describes its investigational product, COMP360, as a proprietary formulation containing a polymorphic crystalline form of psilocybin made to pharmaceutical standards (Compass Pathways, 2026a). Its annual report for 2025 lists United States Patent 10,519,175, granted on 31 December 2019 with claims to methods of treating treatment-resistant depression with oral formulations of its high-purity crystalline psilocybin, and an expected expiry around 2038. The report also records challenges. A petition for post-grant review of that patent, a proceeding in which a third party asks the patent office to reconsider a granted patent, was dismissed in August 2020, and petitions filed in December 2021 by Freedom to Operate, Inc. against two related patents were denied institution on 22 June 2022, with rehearing denied on 23 May 2023 (Compass Pathways, 2026a). Critics have argued that exclusive rights over forms of a compound used for centuries by Indigenous peoples raise questions of fairness and benefit sharing (Celidwen et al., 2023), and Noorani (2020) describes anger in parts of the psychedelic community at efforts to obtain exclusivity.
8.1.2 Investors and Their Incentives
Drug development is expensive. Compass reported a net loss of 287.9 million United States dollars for 2025 and an accumulated deficit of 822.6 million dollars at the end of that year (Compass Pathways, 2026a). On 5 August 2026 it stated that its rolling new drug application was on track to be completed in the fourth quarter of 2026, with commercial launch expected in the first half of 2027 if approved, and it described COMP360 as "expected to be a blockbuster opportunity, if approved" (Compass Pathways, 2026b). These are company statements to investors; the trial results behind them were company-reported toplines that the United States Food and Drug Administration (FDA) had not yet reviewed (Lesson 8).
Two scholarly arguments describe how such pressures can shape the medicine. Noorani (2020) argues that the cost of gaining approval "incentivizes the development of diluted-yet-profitable forms of psychedelic-assisted treatments" and that competitive markets encourage exaggerated claims of efficacy and conflicts of interest in research. Smith and Appelbaum (2021) identify investor-driven companies and the prospect of tax revenue among the forces behind legalization, and warn that marketing not based on evidence may displace evidence-based practice. The strongest argument on the other side is that investor finance has paid for phase 3 programs such as Compass's, which regulators require before approval; the MDMA phase 3 program, by contrast, was initiated and funded by the non-profit MAPS (HCPLive, 2026). Lesson 9 described how the developer of MDMA-assisted therapy reorganized after the FDA's 2024 decision. The next part turns from drug developers to companies that tried to build chains of clinics.
8.2 The Rise and Failure of Commercial Clinic Chains
By 2021, for-profit chains of ketamine clinics had proliferated, and some firms planned networks of psychedelic clinics for indications beyond depression (Smith & Appelbaum, 2021). Smith and Appelbaum note that investigative reports suggest that many ketamine clinics fail to screen patients properly, offer ketamine for indications and at doses not supported by evidence, lack a psychiatrist or other mental health professional on staff, and promote their services with claims far beyond the evidence. Case 12.2 describes one Canadian chain using its own public filings.
Field Trip, based in Toronto, was first incorporated in April 2019, listed on the Canadian Securities Exchange in October 2020, and moved to the Nasdaq stock exchange in July 2021. In August 2022 it split into two companies: Reunion Neuroscience, which kept the drug development business, and Field Trip Health & Wellness, which took the brand, 12 clinic locations and a mobile application (Field Trip Health & Wellness, 2022). The clinics offered ketamine-assisted psychotherapy in Canada and the United States and psilocybin-assisted therapy in the Netherlands, where it was legal (Field Trip Health & Wellness, 2023). In a letter to shareholders on 1 November 2022 the leaders wrote, "Now, our focus is scale," and stated that more than a million people had turned to the company for psychedelic therapies, tools or information (Field Trip Health & Wellness, 2022).
The company's unaudited financial statements for the nine months ending 31 December 2022 reported patient services revenue of about 5.3 million Canadian dollars and a net loss of about 29.6 million dollars, including an impairment of about 5.9 million dollars on leased premises and equipment, with lease obligations of about 29.5 million dollars. The statements disclosed a material uncertainty about the company's ability to continue as a going concern, and in February 2023 its Dallas lease was ended for a termination fee paid by Reunion, the lease guarantor (Field Trip Health & Wellness, 2023). On 22 March 2023 it received an initial court order for creditor protection under the Companies' Creditors Arrangement Act, a federal statute under which an insolvent company can restructure or sell its business under court supervision, and on 31 March 2023 the court authorized a process to seek buyers or investors (Reunion Neuroscience, 2023).
One case cannot show why a whole sector struggled, and the interpretation below is tentative. Field Trip's filings show high fixed costs, mainly long leases on clinic space, against modest revenue from the few treatments it could lawfully offer. Its plan assumed rapid regulatory change, and when that change was slower than expected the costs remained. For patients, the closure or sale of a clinic interrupts care that, in psychedelic-assisted therapy, depends on continuity between preparation, dosing and integration. Supporters of commercial models reply that private capital can build capacity faster than public systems can. A non-profit, group-based model such as Roots to Thrive in Nanaimo, which describes itself as a non-profit health care practice, has different incentives (Roots to Thrive, 2026), although, as of October 2026, none of its published evaluations was a randomized trial (Lesson 10). Whatever the business model, what a service says about itself shapes whom it attracts, which is the subject of the next part.
8.3 Marketing Claims and the Evidence
A marketing claim is any statement a business makes to attract clients. Claims matter ethically because people seeking psychedelic treatment are often distressed and have tried other treatments, and because a claim sets expectations that influence the experience itself (Lesson 5).
Canadian and Oregon rules restrict different kinds of claim. Section 3 of Canada's Food and Drugs Act prohibits advertising any drug to the general public as a treatment, preventative or cure for the conditions listed in its Schedule A.1, which include depression, acute anxiety state and addiction other than nicotine addiction (Food and Drugs Act, R.S.C. 1985, c. F-27, current to 30 September 2026). Health Canada states that the production, sale and possession of magic mushrooms are illegal in Canada unless authorized and that illegally produced drugs are not tested (Health Canada, 2025); Lesson 11 described its 2024 letter to the City of Vancouver about psilocybin storefronts. Oregon's rules prohibit advertising that is deceptive, false or misleading, that targets people under 21, that asserts products are safe because they are regulated or tested, or that claims curative or therapeutic effects not supported by the totality of publicly available scientific evidence (OAR 333-333-6100). Table 12.7 turns these rules into five questions to ask of any claim.
Table 12.7. Five questions for evaluating a marketing claim about psychedelic treatment, with the rule or evidence that each draws on.
| Question | Why it matters | Source |
|---|---|---|
| Does the claim present a drug as a treatment for a named condition such as depression, anxiety or addiction? | In Canada this kind of advertising to the general public is prohibited for Schedule A.1 conditions. | Food and Drugs Act, s. 3 and Schedule A.1 |
| Does it promise a cure, certainty or benefit for everyone? | Trials report average differences and many people who do not respond (Lessons 8 to 10). | OAR 333-333-6100(1)(e) |
| Does it imply that regulation, testing or a government program makes the service safe? | An SAP authorization is not a statement of safety or efficacy, and Oregon bans claims of safety based on regulation. | Health Canada (2023); OAR 333-333-6100(1)(d) |
| Is the product or route lawful where the claim is made? | Sale of psilocybin in Canada is illegal unless authorized. | Health Canada (2025); Lesson 11 |
| Does it disclose risks, costs and the provider's interests? | Practitioner disclosures are one of the seven components of consent. | Marks et al. (2024); Section 1 |
Interactive 12.3 applies Table 12.7 to six statements. The statements are illustrative composites written for this lesson and are not quotations from any real business.
For each illustrative statement, choose its main problem, or choose "Supportable" if it is accurate and appropriately qualified.
Claims about current services rest on present evidence. The final topics concern the medicines and evidence that may exist in the future.
8.4 New Compounds and a Research Agenda
The field's future depends on which compounds reach approval, on how they are delivered, and on whether the evidence improves. Each of these questions has an ethical dimension.
8.4.1 Non-Hallucinogenic Analogues
Lesson 4 explained that some newer compounds are designed to promote neural plasticity without producing the subjective effects of psychedelics. One example, tabernanthalog, was engineered from the structure of ibogaine; in rodents it promoted structural plasticity, reduced alcohol-seeking and heroin-seeking behaviour and had antidepressant-like effects (Cameron et al., 2021). These are animal findings. A 2025 systematic review of non-hallucinogenic analogues for mood and anxiety disorders included five animal studies and one case report and called the findings preliminary (Chen et al., 2025), so the value of such compounds for people remains largely speculative, and research is evolving. If such compounds succeed, treatment could shift toward conventional prescribing with less therapy, which might lower cost and widen access. It would also change the questions raised in this lesson: the debate over whether the experience is necessary (Lesson 5) would become a commercial question, and the origins of a compound derived from a Bwiti sacrament would bear on the benefit-sharing principles of Section 3.
The box below lists recent and pending regulatory developments as of October 2026. Each should be checked before it is relied on, because their status may since have changed.
The regulatory horizon, as of October 2026
In July 2026 the FDA finalized its guidance on clinical investigations of psychedelic drugs, replacing a draft issued in June 2023 and emphasizing functional unblinding, safety monitoring and long-term follow-up (Applied Clinical Trials, 2026). Compass Pathways expected to complete its new drug application for COMP360 in the fourth quarter of 2026 (company-reported; Compass Pathways, 2026b). Resilient Pharmaceuticals, formerly Lykos Therapeutics, was reported in August 2026 to have resubmitted its application for MDMA-assisted therapy without a new phase 3 trial (HCPLive, 2026). In Canada, the Controlled Substances Regulations (SOR/2025-242) came into force on 1 October 2026, and Special Access Program requests for psilocybin and MDMA now proceed under them (Lesson 11). No psilocybin or MDMA product had market authorization, and a private member's bill to permit medical psilocybin, Bill C-286, received first reading on 16 June 2026 and had not been debated (openparliament.ca, 2026).
8.4.2 A Research Agenda
The lessons of this course point to gaps that research would need to close before psychedelic-assisted therapy could be offered widely with confidence. The items below summarize them, each linked to the lesson that developed it.
Define, collect and report adverse events systematically, including harms arising from the therapeutic relationship, with investigators free of conflicts of interest (McNamee et al., 2023; Section 1).
Use designs that measure and reduce functional unblinding and expectancy, as the FDA's 2026 guidance emphasizes (Lesson 5; Applied Clinical Trials, 2026).
Follow participants for longer and compare psychedelic-assisted therapy with established treatments, so that a modest average difference at six weeks can be placed in context (Lesson 8).
Test which therapist skills, team structures and training components affect outcomes and safety, including experiential training, for which a 2024 review found no evidence of an effect on outcomes (Section 2; Villiger, 2024).
Evaluate group and publicly funded models, cost per good outcome and who gains access in real health systems (Section 3).
The research agenda describes what the field needs to learn. The final part asks what a practitioner or planner in British Columbia could responsibly build now, with the evidence and rules that exist.
9.1 Applying This Lesson: Designing a Responsible Service in British Columbia
The course ends with an integrative design problem. Designing a service requires decisions about the indication and its evidence (Lessons 8 to 10), the lawful access route (Lesson 11), the team and its training, consent and safeguards, equity and reciprocity, and evaluation. Figure 12.5 sets out these six decisions in the order in which a planner would usually make them.
Interactive 12.4 walks through the six decisions, splitting the last into two. Choose an option for each; the feedback draws on dated facts from this lesson and earlier lessons and shows where each choice sits relative to the course's practice standard. The standard is one side of a policy debate, so a choice that departs from it can still be argued for, provided the argument addresses the evidence.
The service is hypothetical: an outpatient program in a mid-sized British Columbia city, planned in October 2026. Choose one option for each decision.
Write a two-page plan for the hypothetical service in Interactive 12.4. The service, its city, budget, staff and patients are hypothetical; every fact you rely on must be real and dated. Facts you can use include these: Canada's lawful routes are clinical trials, the Special Access Program (restored for psilocybin and MDMA on 5 January 2022, and operating under the Controlled Substances Regulations since 1 October 2026) and section 56 exemptions (Lesson 11); no psilocybin or MDMA product had market authorization in Canada in October 2026, while esketamine nasal spray was authorized in May 2020 (Lesson 8); Alberta has licensed psychedelic treatment services since 16 January 2023, and no comparable British Columbia rules were identified in the sources for this lesson; British Columbia's Health Professions and Occupations Act took effect on 1 April 2026 and, as of October 2026, listed psychotherapists for regulation in 2027; Roots to Thrive in Nanaimo and TheraPsil in Victoria are non-profit organizations working in group-based therapy, training and access support; and the Declaration Act (2019), Call to Action 22 (2015) and In Plain Sight (2020) set out the commitments described in Section 3.
Your plan should (1) name the indication and intervention and summarize the strength of the evidence, including design, comparator, blinding, effect size and follow-up, from Lessons 8 to 10; (2) state the lawful route and what it requires; (3) describe the team, its regulated professions, training and supervision; (4) set out consent, touch, recording, relationship rules and an independent complaints route; (5) explain how the service will be funded and priced, whom it will reach, how it will provide cultural safety, and how it will approach relationships with First Nations and Indigenous organizations without using any ceremony or traditional knowledge except on their terms; (6) describe how it will monitor outcomes and harms and what it will and will not say in its advertising; and (7) identify the strongest argument against your design and respond to it.
This plan draws together the whole course: how psychedelics act, how the experience is shaped, how the therapy is practised, what the trials show, how access is governed, and the obligations of ethics, training, reciprocity and equity that surround all of it. The reflection and the final assessment below ask you to bring these strands together once more.
Key Takeaways
- 8.1 Patents in this field claim particular forms, formulations and methods of treatment, such as the Compass Pathways patent granted on 31 December 2019 for treatment with crystalline psilocybin, which has survived post-grant challenges. Investor finance has paid for phase 3 programs, while critics argue that the cost of approval and competition for returns encourage diluted-yet-profitable treatments and exaggerated claims.
- 8.2 Field Trip Health & Wellness took on 12 clinic locations, lost about 29.6 million dollars on revenue of about 5.3 million dollars in the nine months to December 2022, and entered creditor protection on 22 March 2023. The case suggests, tentatively, that high fixed costs and plans that depend on rapid regulatory change put patients' continuity of care at risk.
- 8.3 As of October 2026, section 3 of the Food and Drugs Act prohibited advertising a drug to the general public as a treatment for Schedule A.1 conditions such as depression, and Oregon's rules prohibited therapeutic claims beyond the totality of evidence and claims of safety based on regulation. Table 12.7 turns these rules into five questions to ask of any claim.
- 8.4 As of October 2026, the reported effects of non-hallucinogenic analogues such as tabernanthalog came from rodent studies; if they succeed, treatment could shift toward conventional prescribing with less therapy, and their origins would bear on benefit sharing. A research agenda for the field covers harms, blinding and expectancy, durability and comparators, who is studied, therapists and training, delivery and cost, and Indigenous leadership.
- 9.1 Designing a responsible service in British Columbia links six decisions: the indication and its evidence, the lawful route, the team and its training, consent and safeguards, equity and reciprocity, and evaluation and communication. The course's practice standard favours a regulated public health model, and a strong design also answers the counter-arguments, from the wider reach of non-medical models to the role of private investment in paying for trials.
Reflection
A hypothetical investor proposes to open five ketamine clinics in British Columbia within one year, financed by memberships, and to advertise them with client testimonials and the line "Results guaranteed or your money back." The investor plans to add psilocybin "as soon as it is legal." Using Case 12.2 (Field Trip Health, which reported a net loss of about 29.6 million dollars on revenue of about 5.3 million dollars in the nine months to December 2022 and entered creditor protection on 22 March 2023), Table 12.7 and section 3 of the Food and Drugs Act, evaluate the proposal and describe an alternative that keeps the useful parts of private investment while meeting the course's practice standard.
The proposal repeats several features of Case 12.2. Field Trip expanded to 12 locations, carried about 29.5 million dollars in lease obligations, and lost far more than it earned while waiting for regulatory change; when that change came slowly, it entered creditor protection, and patients' care was put at risk. Opening five clinics in a year on membership revenue, with a plan that depends on psilocybin becoming legal on an uncertain timeline, creates the same exposure.
The advertising fails Table 12.7. A guarantee and testimonials promise more than the evidence supports, since trials report average differences and many people do not respond, and they disclose no risks or financial interests. Advertising a drug to the general public as a treatment for depression, a Schedule A.1 condition, would be prohibited under section 3 of the Food and Drugs Act.
An alternative would start with one clinic offering ketamine-assisted psychotherapy for treatment-resistant depression under existing approvals, staffed by regulated professionals with supervision, sober consent and an independent complaints route. Investment could pay for facilities, training and a public evaluation that reports harms and null results. Advertising would be limited to accurate, dated statements, and any future psilocybin service would wait for an authorized route, such as Special Access Program requests or a trial.
Minimum 20 characters required.
Question 1: Which statement about Field Trip Health & Wellness is supported by public filings?
Question 2: What does section 3 of Canada's Food and Drugs Act prohibit?
Question 3: What did Cameron et al. (2021) report about tabernanthalog?
Question 4: Which kind of statement does Oregon's advertising rule for psilocybin services (OAR 333-333-6100) prohibit?
Final Assessment
Bringing It All Together
This lesson closed the course by asking what the evidence, pharmacology and access routes of earlier lessons require of the people who practise psychedelic-assisted therapy and of the systems that deliver it. Section 1 showed that the altered state weakens the ordinary protections of consent, so agreements are made while the person is sober and safeguards surround the practitioner; the 2019 disclosure from a Canadian trial site showed that co-therapy, recording and supervision can fail when they are not independent and when misconduct falls outside regulation. Section 2 described who may provide care in British Columbia, the training programs and their dated status, the competencies the field has proposed and the unresolved debate over experiential training.
Section 3 turned to reciprocity and fairness: the eight ethical principles of traditional Indigenous medicine, Two-Eyed Seeing, the Nagoya Protocol and the overharvesting of sacred plants, the composition of trial samples, and the clinician time that makes the therapy expensive. Section 4 examined patents, investor incentives, the failure of a Canadian clinic chain, the rules on marketing claims and the field's future, and asked you to design a responsible service in British Columbia.
Across the lesson, the course's practice standard favoured a regulated public health model with licensed providers, training standards and equitable funding. That standard is one side of a policy debate, and the counter-arguments, from the wider reach of non-medical models to the role of private investment in paying for trials, deserve the same scrutiny as the standard itself.
Key Takeaways from this lesson
- The altered state weakens decision-making, increases suggestibility and intensifies transference, so consent to touch, recording and other conditions is obtained while the person is sober and renewed before any further session. Marks et al. (2024) identified seven components of consent to psychedelic medicine, including the limited role of touch, the potential for abuse or coercion and practitioner disclosures.
- Health Canada's 2022 trial expectations, Oregon's rules and Canadian professional guidance all prohibit sexual contact with clients, and Oregon extends the prohibition to one year after the last service.
- In Case 12.1, two providers, recording and supervision were all in place and failed, because one co-therapist did not report the other, the video was reviewed years later, and the sexual relationship began after the active treatment sessions with a therapist who was outside any regulator.
- In British Columbia, the Health Professions and Occupations Act replaced the Health Professions Act on 1 April 2026, and, as of October 2026, psychotherapists were listed to join a regulatory college in 2027. Canadian training changed quickly: Vancouver Island University cancelled its certificate on 20 November 2025, the University of Ottawa's master's degree began in 2024, the latest Michener deadline found was November 2024, and the MAPS Canada school's platform status was uncertain in October 2026.
- A 2024 review (Villiger) found no evidence that therapists' personal psychedelic experience improves outcomes, and research on training is evolving; in Canada, as of October 2026, lawful experiential training had depended on ministerial exemptions that had been granted, refused and litigated.
- The eight principles of Celidwen et al. (2023), Two-Eyed Seeing, the Declaration Act and Call to Action 22 ask services to follow Indigenous direction and use no ceremony or knowledge without free, prior and informed consent, and Canada was not a Party to the Nagoya Protocol in October 2026.
- Most participants in psychedelic studies from 1993 to 2017 were non-Hispanic White. Clinician time drives the cost of psychedelic-assisted therapy, and Oregon's 2025 data show that its privately paid services mostly reached clients with higher household incomes, among those who reported income.
- Patents, investor pressure and clinic chains shape the field: Field Trip Health & Wellness entered creditor protection in March 2023, and, as of October 2026, Canadian and Oregon rules restricted therapeutic claims that go beyond the evidence. As of October 2026, the findings on non-hallucinogenic analogues came mainly from animal studies, and a research agenda for the field runs from harms and blinding to Indigenous leadership.
- A responsible service in British Columbia links the indication and its evidence, a lawful route, a trained and supervised team, sober consent and safeguards, equity and reciprocity, and honest evaluation.
Core Concepts Reviewed
Section 1: decision-making capacity, suggestibility, transference, countertransference, boundary drift, fiduciary duty, the seven components of consent, supportive touch rules, zero tolerance for sexual contact, supervision, documentation and the practitioner's inner work.
Section 2: prescribers and regulated professions in British Columbia, the Health Professions and Occupations Act, three models of who delivers care, dated training programs, Phelps's six competencies, later competency frameworks, and the experiential training debate and Toth v. Canada.
Section 3: the eight ethical principles of traditional Indigenous medicine, free, prior and informed consent, Two-Eyed Seeing, UNDRIP Articles 24 and 31, the Declaration Act, In Plain Sight, the Nagoya Protocol, sacred plant conservation, trial diversity, and clinician time, cost and access.
Section 4: patents and post-grant review, investor incentives, the Field Trip case and creditor protection, Food and Drugs Act section 3 and Schedule A.1, Oregon's advertising rule, non-hallucinogenic analogues, the regulatory horizon and a research agenda, and the design of a responsible service.
Before the final assessment, bring the strands of the course together in one recommendation for a British Columbia health authority.
Reflection
Imagine you are advising a British Columbia health authority in October 2026 on whether to plan a hypothetical psilocybin-assisted therapy service for treatment-resistant depression. You know the following. Two company-reported phase 3 trials of COMP360 found differences of 3.6 and 3.8 points on the Montgomery-Asberg Depression Rating Scale at week 6 compared with placebo or a 1 milligram dose. No psilocybin product has Canadian market authorization, so each patient would need a Special Access Program request, which Health Canada says is not a statement that the drug is safe or effective. A course of therapy might cost about 14,600 dollars under hypothetical assumptions. Oregon's private-pay services have mostly reached people with higher incomes. British Columbia's In Plain Sight review found widespread Indigenous-specific racism in health care. Write a recommendation: should the authority proceed, and if so under what conditions? Address the evidence, the access route, the team and safeguards, equity and cultural safety, and evaluation.
I would recommend a small, time-limited service planned as an evaluated pilot, with conditions. The evidence supports cautious use: two company-reported phase 3 trials found statistically clear but modest average differences of 3.6 and 3.8 points, results the FDA had not yet reviewed, so patients should be told that many will not benefit and that durability beyond six months is uncertain. Because no product is authorized, the pilot would serve only patients for whom conventional treatments have failed or are unsuitable, through individual Special Access Program requests, and consent would explain that an authorization is not a statement of safety or efficacy.
The team would include a prescribing physician, a licensed therapist and a second clinician at every session, with a nurse for monitoring, regular supervision and sober written consent covering touch, recording and relationships. An independent complaints route would sit outside the team. To avoid reproducing Oregon's pattern, the service would be publicly funded with travel support for rural patients, and it would work with local First Nations and Indigenous health organizations on cultural safety and anti-racism training, using no ceremony without free, prior and informed consent. Finally, it would measure outcomes and harms systematically, report results publicly, including null findings, and stop or change course if harms or inequities appeared. If funding for equitable access and evaluation cannot be secured, I would advise waiting, or joining an authorized trial, until it can.
Minimum 30 characters required.
Final Knowledge Assessment
Question 1: At the peak of a hypothetical psilocybin trial session, a participant asks a therapist for a kind of touch that is not in the written plan. Which response best combines the standards of Sections 1 and 2?
Question 2: The CBC reported in 2022 that no official body could investigate the therapist at the centre of Case 12.1. Why, and how does British Columbia's 2026 change in health profession regulation bear on this?
Question 3: Holding the session schedule constant in Calculator 12.1, which change most directly reduces clinician hours per participant?
Question 4: Most of Oregon's 2025 psilocybin clients who reported household income earned more than 95,375 US dollars. What does this most directly suggest to a British Columbia planner concerned with equity?
Question 5: Which pair gives British Columbia services both a provincial legal commitment and a health-system finding relevant to Indigenous cultural safety?
Question 6: A hypothetical clinic's website states, "Health Canada approved our psilocybin program, so it is completely safe." Which statement best describes the problem?
Question 7: Marks et al. (2024) list relevant practitioner disclosures as a component of consent. Which situation from this lesson best shows why?
Question 8: Which statement about experiential training with psilocybin in Canada is accurate as of October 2026?
Question 9: Which combination best reflects the principles of Celidwen et al. (2023) for a hypothetical British Columbia service?
Question 10: In the MAPP trials the comparison group received the same therapy hours with placebo. Why does multiplying the full course cost by the number needed to treat overstate the cost of adding MDMA?
Question 11: Which feature of the altered state is most directly supported by the placebo-controlled LSD study of Carhart-Harris et al. (2015)?
Question 12: Which statement about the ethnoracial composition of psychedelic trials is accurate?
Question 13: A hypothetical planner proposes investor-funded rapid expansion of a clinic chain. Which lesson from Case 12.2 is most relevant?
Question 14: Which statement about Two-Eyed Seeing (Etuaptmumk) is accurate?
Question 15: Which plan best fits the course's practice standard for a lawful psilocybin service in British Columbia in October 2026?
Glossary: Key Terms, People & Frameworks
📚 Reference page, available throughout the lesson
Definitions of the key terms, frameworks and people in Lesson 12, with dates where a rule, program or decision may have changed.